Cargando…
Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database
SIMPLE SUMMARY: Data on immune checkpoint inhibitor (ICI)-related cytopenias are scarce. The aim of the study was to further characterize grade ≥ 2 ICI-related cytopenias using the French pharmacovigilance database. Immune thrombocytopenia and autoimmune hemolytic anemia were the most frequently rep...
Autores principales: | Martin, Mickaël, Nguyen, Hoan-My, Beuvon, Clément, Bene, Johana, Palassin, Pascale, Atzenhoffer, Marina, Rouby, Franck, Sassier, Marion, Pérault-Pochat, Marie-Christine, Roblot, Pascal, Allouchery, Marion, Puyade, Mathieu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599380/ https://www.ncbi.nlm.nih.gov/pubmed/36291814 http://dx.doi.org/10.3390/cancers14205030 |
Ejemplares similares
-
Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review
por: Allouchery, Marion, et al.
Publicado: (2022) -
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020) -
Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
por: Allouchery, Marion, et al.
Publicado: (2021) -
Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
por: Garon-Czmil, Julie, et al.
Publicado: (2019) -
Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)